United States securities and exchange commission logo October 18, 2021 Yulin Wang Chief Executive Officer Meihua International Medical Technologies Co., Ltd. 88 Tongda Road, Touqiao Town Guangling District, Yangzhou, 225000 People s Republic of China Re: Meihua International Medical Technologies Co., Ltd. Amendment No. 3 to Registration Statement on Form F-1 Filed September 24, 2021 File No. 333-258659 Dear Mr. Wang: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Amendment No. 3 to Registration Statement on Form F-1 filed September 24, 2021 Cover Page 1. Please expand your disclosure on the prospectus cover page to provide a description of how cash is transferred through your organization. State whether any transfers, dividends, or distributions have been made to date. Yulin Wang FirstName LastNameYulin Wang Meihua International Medical Technologies Co., Ltd. Comapany October 18,NameMeihua 2021 International Medical Technologies Co., Ltd. October Page 2 18, 2021 Page 2 FirstName LastName Prospectus Summary Summary of Significant Risk Factors, page 10 2. Please prominently disclose as significant risk factors the risks related to doing business in China as discussed on page 31. You may contact Tracey Houser at 202-551-3736 or Brian Cascio at 202-551-3676 if you have questions regarding comments on the financial statements and related matters. Please contact Jane Park at 202-551-7439 or Celeste Murphy at 202-551-3257 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joe Laxague, Esq.